​

Milestone Pharmaceuticals (MIST) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MIST Stock Forecast

Milestone Pharmaceuticals (MIST) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $10.00 and a low of $10.00. This represents a 1119.51% increase from the last price of $0.82.

- $2 $4 $6 $8 $10 High: $10 Avg: $10 Low: $10 Last Closed Price: $0.82

MIST Stock Rating

Milestone Pharmaceuticals stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

MIST Price Target Upside V Benchmarks

TypeNameUpside
StockMilestone Pharmaceuticals1119.51%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.82$0.82$0.82
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 252-2--4
Mar, 25211--4
Feb, 25211--4
Jan, 25211--4
Dec, 24211--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 22, 2022Piper Sandler$10.00$7.1539.86%1119.51%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 01, 2025Cowen & Co.BuyHolddowngrade
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 14, 2024H.C. WainwrightBuyBuyhold
Aug 22, 2024Rodman & RenshawBuyinitialise
Jul 02, 2024H.C. WainwrightBuyBuyhold
Dec 27, 2023Cowen & Co.OutperformOutperformhold
Apr 26, 2022Piper SandlerOverweightupgrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.02$-1.35$-1.39$-0.67----
Avg Forecast$-1.06$-1.43$-1.37$-0.63$-0.99$-0.56$0.26$1.08
High Forecast$-0.23$-0.10$-1.36$-0.59$-0.51$-0.13$0.44$1.86
Low Forecast$-2.20$-3.06$-1.38$-0.66$-1.39$-0.96$0.06$0.25
Surprise %-3.77%-5.59%1.46%6.35%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.00M$5.00M$1.00M-----
Avg Forecast$15.00M$2.00M$1.00M$1.80M$4.34M$47.30M$142.50M$244.13M
High Forecast$27.36M$3.76M$1.56M$2.80M$6.20M$73.59M$221.70M$379.82M
Low Forecast$5.95M$572.36K$405.62K$730.11K$1.85M$19.19M$57.80M$99.02M
Surprise %-150.00%------

Net Income Forecast

$-150M $-100M $-50M $0 $50M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.63M$-57.13M$-59.69M-----
Avg Forecast$-45.53M$-61.21M$-58.85M$-26.98M$-42.61M$-23.91M$11.03M$46.39M
High Forecast$-9.82M$-4.41M$-58.42M$-25.24M$-21.73M$-5.44M$18.99M$79.91M
Low Forecast$-94.30M$-131.38M$-59.28M$-28.28M$-59.66M$-41.19M$2.51M$10.55M
Surprise %-6.37%-6.66%1.42%-----

MIST Forecast FAQ

Is Milestone Pharmaceuticals stock a buy?

Milestone Pharmaceuticals stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Milestone Pharmaceuticals is a favorable investment for most analysts.

What is Milestone Pharmaceuticals's price target?

Milestone Pharmaceuticals's price target, set by 6 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $10 at the low end to $10 at the high end, suggesting a potential 1119.51% change from the previous closing price of $0.82.

How does Milestone Pharmaceuticals stock forecast compare to its benchmarks?

Milestone Pharmaceuticals's stock forecast shows a 1119.51% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Milestone Pharmaceuticals over the past three months?

  • April 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 50.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 50.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Milestone Pharmaceuticals’s EPS forecast?

Milestone Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.99, marking a 47.76% increase from the reported $-0.67 in 2024. Estimates for the following years are $-0.56 in 2026, $0.26 in 2027, and $1.08 in 2028.

What is Milestone Pharmaceuticals’s revenue forecast?

Milestone Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $4.34M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $47.3M, followed by $142.5M for 2027, and $244.13M for 2028.

What is Milestone Pharmaceuticals’s net income forecast?

Milestone Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-42.612M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-23.912M in 2026, $11.03M in 2027, and $46.39M in 2028.